BPC-157

A synthetic fragment modeled on a gastric protective protein — the most talked-about healing peptide in the world.

⚠ Safety first — read this before anything else on this page

Approval status: BPC-157 is not FDA-approved for any use. As of November 2026 it sits inside a draft federal enforcement-discretion policy for state-licensed compounding pharmacies — discretion is not approval, and it does not cover research-chemical sales.

What has actually happened to people:

FDA's July 2026 advisory-committee briefing detailed three adverse-event reports: nine days of injection-site redness and swelling (a 55-year-old woman also using a compounded thymosin product); shortness of breath after an injection (a 28-year-old man); and skin and gum darkening after a blended product labeled 'research purposes only.'
KFF Health News (October 13, 2026) described FDA adverse-event entries including a hospitalized 36-year-old woman and a 48-year-old man hospitalized with a condition described as life-threatening.
Users of one gray-market brand reported prolonged fatigue, anxiety and anhedonia afterward (KFF, October 13, 2026 — patient-reported; cause unverified).

What nobody knows: There are no human safety studies of BPC-157 — no completed human trial safety data, no carcinogenicity studies, no interaction data with any medication. Long-term effects are unknown — not known to be safe, unknown.

Get medical care now if:

Swelling of the lips or tongue, or trouble breathing, after an injection — call emergency services.
An injection site that stays red and swollen for days, or spreads instead of settling.
A new lump or sore at an injection site appearing one to several weeks later — the delayed infection pattern; it needs a clinician, and standard antibiotics may fail on the organisms involved.

Who should stay away: Anyone with a cancer history — the compound drives new blood-vessel growth (VEGFR2), the tumor question is unresolved, and avoiding GH-axis and angiogenic compounds after cancer is the clinician community's own stated red line (Dr. Froese). Also: minors, anyone pregnant, and tested athletes — BPC-157 is prohibited at all times under WADA's S0 class.

The product problem: In independent testing of 469 gray-market BPC-157 samples from 69 vendors (Finnrick Analytics), the measured quantity varied up to ±80% of what the label promised, about 8% of samples carried quantifiable endotoxin, and 68% of vendors graded C or below.

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

What it is

A synthetic fragment modeled on a gastric protective protein — the most talked-about healing peptide in the world.

What creators claim

Creators including Dr. Ashley Froese describe BPC-157 as a tissue-repair signal — in her framing, a ’local architect’ that increases blood-vessel growth signaling (VEGF/VEGFR2) and nitric-oxide pathways; it is the base of the Wolverine stack. Dr. Edwin Lee notes on the record both the promise and the risks, including anaphylaxis.

What the evidence shows

Weak in humans. A 2025 systematic review screened 544 papers and found 36 studies — 35 preclinical and one small clinical report. There are no completed human efficacy trials establishing benefit for any diagnosis (USADA, August 2026). Most of the literature traces to one Croatian research group — a concentration independent critics flag.

The human evidence, counted

A 2025 systematic review (Vasireddi et al., HSS Journal) screened 544 papers and found 36 studies — 35 preclinical and 1 clinical. The complete published human record is three small uncontrolled reports, about 30 people in total: a retrospective knee-pain series (12 patients; 7 of 12 reported relief beyond six months; no control group), an intravenous safety pilot (2 subjects), and an interstitial-cystitis series (12 subjects) — all from private clinical practice (McGuire et al., 2025). Exactly one human trial was ever registered, NCT02637284 (Phase I, begun 2015, ~42 healthy volunteers); its registry record was never updated after December 2015 and no results were ever posted. There are no completed human efficacy trials for any diagnosis.

Who wrote the literature

More than 80% of the 190+ papers in the published literature list Predrag Sikirić or Sven Seiwerth — the University of Zagreb group that created the compound — as first or senior author (Józwiak et al., Pharmaceuticals, 2025; an independent 2026 count found 175 of 227 papers sharing Sikirić as an author). The Zagreb group disputes its critics in print; the authorship arithmetic is not disputed. Why that concentration matters — and the undisclosed company stakes journalists found behind it — is its own page: The One-Lab Problem.

The patent story

Patent priority 1989; U.S. Patent 5,288,708 granted 1994. Croatian pharma Pliva licensed the compound in 1993 (developed as PL-14736 for ulcerative colitis); GSK acquired Pliva’s research arm in 2006 and dropped the program. The molecule patent expired around 2011 — which is the most plausible reason no sponsor has funded definitive trials: with no exclusivity, there is no return on proving it. What the discoverer holds today, per STAT News and Undark (February 2026), is part-ownership of PharmaCotherapia — sponsor of the abandoned trial above — and the CEO seat at Diagen, which holds a live formulation patent on a stable BPC-157 salt advertised for sale. Those interests were not disclosed in the papers the reporters reviewed.

What’s actually in the vial

Independent testing platform Finnrick Analytics’ BPC-157 dataset (469 samples from 69 vendors, December 2024–March 2026): labeled purity was mostly high (96.25–99.95%), but quantity varied up to ±80% of what the label promised, about 8% of samples carried quantifiable endotoxin, and 68% of vendors graded C or below. Across all compounds, Finnrick reports roughly one in three gray-market samples fail basic expectations (February 2026). For BPC-157 specifically, the documented failure modes are wrong quantity and endotoxin — the peer-reviewed heavy-metal findings (lead, arsenic) come from other falsified peptides. See Testing and Contaminated Products & Forged Lab Reports.

Forms it is discussed in

Injectable (the default creator form) and oral/capsule (disputed — see the forms debate in our census research: BPC-157 is itself a gastric peptide, which is the core of the pro-oral claim); sublingual products are also marketed.

Dangers on record

Anaphylaxis risk noted by Dr. Lee; prolonged fatigue, anxiety and anhedonia reported by users of one gray-market brand (KFF, October 13, 2026); FDA adverse-event hospitalizations are on record. Both BPC-157 and its stack partner drive new blood-vessel growth, which is the basis of critics’ theoretical cancer concern — graded honestly, with what is unknown stated plainly, on Cancer and Peptides. See also Dangers.

Legal status (as of November 7, 2026)

Not FDA-approved. Removed from the 503A Category 2 list in April 2026 (nominations withdrawn — not a safety finding). The PCAC voted 8–6 in July 2026 to recommend it for the 503A Bulks List; it is not on that list. It IS one of the six peptides in the October 30, 2026 HHS enforcement-discretion policy (acetate form, single-ingredient, conditions apply) — discretion is not approval and not compounding authorization. Banned in sport (WADA S0).